Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could detoxing metals boost chemo for leukemia?

NCT ID NCT03630991

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check for side effects. The idea is that reducing certain metals in the blood and bone marrow might make the cancer easier to treat.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Edetate calcium disodium and succimer (metal-lowering drugs)

What this could lead to

If it works, this could point toward a way to make chemotherapy more effective for blood cancers by reducing harmful metal levels.

What could go wrong

This is a very early phase 1 trial with only 58 people, so it is not yet known if the approach is safe or effective. The main goal is just to find a safe dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia with multilineage dysplasia blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative disease myelodysplastic/myeloproliferative neoplasm Myeloproliferative Disorders myeloproliferative neoplasm therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE HIGH RISK MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM MYELOPROLIFERATIVE NEOPLASM RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE RECURRENT MYELODYSPLASTIC SYNDROME RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE REFRACTORY MYELODYSPLASTIC SYNDROME SECONDARY ACUTE MYELOID LEUKEMIA SECONDARY MYELODYSPLASTIC SYNDROME VERY HIGH RISK MYELODYSPLASTIC SYNDROME

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact